middle.news
How Memphasys Is Driving Felix System Sales Despite FY25 AUD 4.94M Loss
3:43am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
How Memphasys Is Driving Felix System Sales Despite FY25 AUD 4.94M Loss
3:43am on Saturday 30th of August, 2025 AEST
Key Points
FY25 net loss widened to AUD 4.94 million
Felix System completed Phase III clinical trials and CE Mark application lodged
Early sales initiated in Japan, New Zealand, Canada, UAE, and India
RoXsta oxidative stress platform progressing with patent filing and pilot studies
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Memphasys (ASX:MEM)
OPEN ARTICLE